Bengaluru: Johnson & Johnson (J & J) said on Tuesday in talks with the Indian government to explore ways to accelerate the delivery of the covid-19 single-shot vaccine in the country.
The Economic Times newspaper reported on Tuesday that the company would no longer conduct a local trial for its vaccine, after India’s decision to bridge the clinical trial for vaccines approved by regulators in other countries.
J & J did not determine in his comments whether to have canceled the trial.
The US-based company said in April it was seeking approval to conduct clinical studies bridging from Janssen Covid-19 vaccine candidate in India.
But at the end of May-May, the country canceled the local trial for the “established” vaccine produced in other countries.
More than 41 million doses of vaccines are given throughout India in the past week, when experts say that broad vaccination remains one of the best tools to avoid the type of destruction that the state views during the second wave of pandemics.